Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard(Foundation Medicine (United States)), Pasi A. Jänne(Harvard University), James Chih‐Hsin Yang(National Taiwan University Hospital), Cloud P. Paweletz(Massachusetts General Hospital), Mireille Cantarini(AstraZeneca (United Kingdom)), Ryan S. Alden(AstraZeneca (Singapore)), Kenneth S. Thress(AstraZeneca (United States)), Rachael Lawrance(AstraZeneca (Singapore)), J. Carl Barrett(National Institute of Environmental Health Sciences)
Cited by 843
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k